Corcept Therapeutics在欧洲ALS治疗网络2025年年会上展示了Dazucorilant在ALS患者中的DAZALS研究结果，DAZALS未达到其主要终点，即与安慰剂相比，ALS功能评定量表修订版的结局改善

2025-06-05 18:08

DAZALS did not meet its primary endpoint of improved outcome in the ALS Functional Rating Scale-Revised (ALSFRS-R) in patients who received dazucorilant compared to patients who received placebo
DAZALS met its secondary endpoint of improved overall survival at week 24 of the study in patients who received 300 mg of dazucorilant compared to patients who received placebo
Exploratory analysis at the one-year mark shows continued significant improvement in overall survival between patients who received 300 mg of dazucorilant and those who received placebo only
Corcept seeking guidance from United States and European regulators on optimum path forward